14 Recent Developments in Cell and Gene Therapy as of March 22, 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. EdiGene, a gene-editing company based in Beijing, China, has entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital (BCH) for intellectual property rights covering the upregulation of fetal hemoglobin […]

VIDEO: 5 Key Trends in Cell and Gene Therapy

Learn about these 5 key trends based on research featured in Cell Therapy and Gene Therapy Markets, 2021-2031 (published Feb. 2022), a recent report by Kalorama Information Cell and gene therapy products are transforming the treatment of many acquired diseases such as cancer, diabetes, Parkinson’s disease and genetic diseases to correct defective genetic material. Additionally, […]

Veterinary Diagnostics: COVID-19 Pandemic Can’t Slow Momentum of $3.5 Billion Market

  “The veterinary diagnostics market represents a fast-growing opportunity to IVD companies and others able to capitalize on the unfailing need to ensure agricultural productivity and the growth in consumer spending on companion animals.” – Kalorama Information   The veterinary diagnostics market has experienced steady growth through the ravages of the pandemic and is forecast […]

11 Recent Developments in Cell and Gene Therapy as of March 2022

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The US Patent and Trademark Office has ruled against a patent challenge by the University of California, Berkeley (UC Berkeley) over patents awarded to the Broad Institute of MIT and […]

Tenfold Growth for $5.2 Billion Cell and Gene Therapy Market from 2021-2031

“Oncology, cardiovascular-blood and genetic conditions will be key contributors to the cell and gene therapy market’s strong performance through 2031.” – Kalorama Information   It is an exciting and interesting time for companies involved in cell and gene therapy as the industry is forecast to grow tenfold between 2021 to 2031, according to leading medical […]

Funding for Cell and Gene Therapies Exceeded 70 Billion Last Year: Kalorama Report

Total funding from all sources for cell and gene therapy companies totaled  $70.8 billion last year, according to a compilation of deals performed by Kalorama Information as part of its recent report.  The growth in money being injected into cell and gene therapy companies continues to grow in 2022, according to the firm’s report: Cell […]

Cardiovascular Disease Pumps Sales of Cardiac Markers to $2,517 Million

“With the incidence of cardiovascular disease escalating, cardiac markers are in huge demand and a constant subject of research for improvement.” – Kalorama Information Despite improvements in treatment and increased public awareness about prevention, cardiovascular disease (CVD) is still the leading cause of death worldwide. CVD causes half of all deaths in several developed countries […]

10 Recent Developments in Cell and Gene Therapy

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. Intellia Therapeutics, based in Cambridge, MA, has acquired Berkeley, CA-based Rewrite Therapeutics, a private biotech company specializing in developing novel genome editing technologies. Rewrite’s Rewriter platform utilizes CRISPR-guided DNA polymerases […]

Infographic: Blood Screening & Blood Transfusions

“The United States is the biggest user of blood transfusions—approximately 5 million people in the U.S. receive blood and blood components through 10.9 million transfusions per year.” – Kalorama Information   The global $2.5 billion blood screening market is evolving on many levels, and despite it’s maturity the industry is poised for growth through 2026 […]

Coagulation Tests Near 4 Billion, Per IVD Newsletter

The 2021 global market for coagulation tests (lab-based and all POC) neared 4 billion last year.    PT and d-dimer tests lead revenues, per Kalorama’s In Vitro Diagnostic Business Outlook.  The publication focuses on one aspect of the IVD market in each issue. The publication comes out 2 times a month.  This issue focused on […]